Accessibility Menu
Nemaura Medical logo

Nemaura Medical(OTC) NMRD

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-100%
1 Year-99%
1 Month-99%
$0.00
+0.00%
+0.00Today
Nemaura Medical last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-31
Nemaura Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-24
1 month-99%USD 0.002026-06-29
3 month-99%USD 0.002026-05-01
Year to date+0%USD 0.002025-12-31
1 year-99%USD 0.002025-07-31
3 year-100%USD 0.902023-08-01
5 year-100%USD 7.582021-07-30
Since inception-100%USD 2.502014-12-18

Nemaura Medical Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

-$1.55M

Net Income (TTM)

-$6.30M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-2632.23 (Low)

Price

$0.00

Volume

5,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.05

Estimated Earnings Date

Aug 10, 2026

NMRD News

man_large_surprised__getty

Why Micro Cap Nemaura Medical Crashed 39.5% Today

Todd CampbellDec 18, 2018
rocket ship GettyImages-515682468

Why Micro Cap Nemaura Medical Skyrocketed 32% Yesterday

Todd CampbellSep 13, 2018

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nemaura Medical

Nemaura Medical Inc. is a medical technology company focused on developing innovative diagnostic medical devices. The flagship product, sugarBEAT, is a non-invasive continuous glucose monitoring system designed for individuals with diabetes. Additionally, Nemaura offers proBEAT, a wellness guidance service aimed at improving blood sugar management.

Products and Services
  • sugarBEAT: Non-invasive continuous glucose monitoring system
  • proBEAT: Wellness guidance service for blood sugar management
  • Specialized programs for diabetes prevention and reversal
Growth Outlook
  • Expansion into diabetes management market projected to grow significantly
  • Increasing prevalence of diabetes enhances demand for innovative solutions
  • Partnerships with healthcare providers may drive product adoption
Financial Highlights
  • Recent quarterly net income of -$2.16 million reflects ongoing investment in R&D
  • Trailing twelve months revenue remains at $0, indicating early-stage development
  • Cash and cash equivalents decreased to $137,416, necessitating strategic financial planning
Nemaura Medical Inc. operates in the healthcare sector, specifically within the medical devices industry. The company is dedicated to addressing the growing challenges associated with diabetes management through its innovative products. The sugarBEAT system offers a unique solution for continuous glucose monitoring, which is crucial for individuals managing diabetes. The proBEAT service complements this by providing users with insights and guidance on their blood sugar levels. The growth outlook for Nemaura is promising, driven by the increasing prevalence of diabetes and the demand for effective management solutions. The company's focus on partnerships with healthcare providers may further enhance its market presence and product adoption. Financially, Nemaura is in a developmental phase, as indicated by the recent quarterly net income and trailing twelve months revenue figures. The decrease in cash reserves highlights the importance of strategic financial management as the company continues to invest in research and development. Overall, Nemaura Medical Inc. presents an intriguing opportunity for investors interested in the medical technology sector, particularly in the diabetes management space.
AI Generated • Jul 23, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

38

CEO

Dewan Fazlul Hoque Chowdhury, PhD

Website

www.nemauramedical.com

Headquarters

New York City, NY 10019, US

NMRD Financials

Key Financial Metrics (TTM)

Gross Margin

-1916.30%

Operating Margin

-12454.23%

Net Income Margin

-18358.00%

Return on Equity

249.27%

Return on Capital

-116.79%

Return on Assets

-97.12%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

40.35M

Volume

5.00K

Avg. Volume

1.24K

Financials (TTM)

Gross Profit

-$4.67M

Operating Income

-$9.71M

EBITDA

-$4.50M

Operating Cash Flow

-$9.57M

Capital Expenditure

-$177.22K

Free Cash Flow

-$9.74M

Cash & ST Invst.

$137.42K

Total Debt

$19.64M

Nemaura Medical Performance Analysis

Nemaura Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-03-31USD 503,906N/A
20232023-03-31USD 77,044-84.7%
Nemaura Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-03-31-51589.4%
Q12023-06-30100.0%
Q22023-09-30N/A
Q32023-12-31N/A
Nemaura Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-03-31USD -0.59N/A
20232023-03-31USD -0.57-4.3%
Nemaura Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-03-3181.5%
Q12023-06-30-582.6%
Q22023-09-3053.8%
Q32023-12-31-79.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$80.43K

-174939.1%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

36

N/A

Net Income

-$2.16M

-25.9%

EBITDA

-$155.37K

+71.1%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$137.42K

-98.1%

Total Debt

$19.64M

-2.1%

Accounts Receivable

$247.79K

+878.6%

Inventory

$3.67M

+56.1%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$19.64M

+70.6%

Return on Assets

-97.12%

N/A

Return on Invested Capital

1.25%

N/A

Free Cash Flow

-$1.49M

+6.8%

Operating Cash Flow

-$1.48M

+4.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VIVEViveve Medical, Inc.
$0.00+0.00%
VICARafina Innovations Inc.
$0.00+0.00%
TNGNQTengion, Inc.
$0.00+0.00%
KLDOKaleido Biosciences, Inc.
$0.00+900.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About NMRD

What is the current price of Nemaura Medical?

Nemaura Medical is trading at $0.00 per share.

What is the 52-week range for Nemaura Medical?

Over the past 52 weeks, Nemaura Medical has traded between $0.00 and $0.05.

How much debt does Nemaura Medical have?

As of the most recent reporting period, Nemaura Medical reported total debt of $20.03M.

How much cash does Nemaura Medical have on hand?

Nemaura Medical reported $10.11M in cash and cash equivalents in its most recent financial results.

What is Nemaura Medical’s dividend yield?

Nemaura Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services